Aclaris Therapeutics, Inc. (ACRS)
$3.83+1.06%Close
SELLCRISIS · day 11
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $535M
- Beta
- 0.80
- P/E (TTM)
- -6.38
- Short % float
- 17.40%
- Days to cover
- 6.5
- SI change
- +13.2%
- 1W
- -12.76%
- 1M
- -30.49%
- vs SPY 1W
- -13.92%
- vs SPY 1M
- -33.48%
Industry peers
FMP comparable companies · ranked by market cap
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$45.95-0.56%
- TRAXSELLFirst Tracks Biotherapeutics Inc$1.1BQ 81$31.85-0.50%
- ODTXSELLOdyssey Therapeutics, Inc.$913MQ 38$19.00+4.86%
- MLTXSELLMoonLake Immunotherapeutics$910MCRISISQ -0$10.82+2.27%
- ALMSSELLAlumis Inc.$884MCRISISQ 2$7.16+2.73%
- ATTOSELLAttovia Therapeutics, Inc.$698MQ -44$16.21-0.61%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on ACRS?
- LOPJLB’s latest quantitative signal on Aclaris Therapeutics, Inc. (ACRS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ACRS in?
- Aclaris Therapeutics, Inc. (ACRS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Aclaris Therapeutics, Inc. (ACRS) do?
- Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial un…